New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More
Last Close
Sep 16  •  01:38PM ET
0.6880
Dollar change
+0.0040
Percentage change
0.58
%
Index- P/E- EPS (ttm)-0.86 Insider Own2.19% Shs Outstand44.66M Perf Week-1.85%
Market Cap30.73M Forward P/E- EPS next Y-0.10 Insider Trans1.56% Shs Float43.68M Perf Month-20.29%
Enterprise Value50.26M PEG- EPS next Q-0.11 Inst Own4.57% Short Float2.79% Perf Quarter-31.20%
Income-24.08M P/S- EPS this Y51.12% Inst Trans49.33% Short Ratio1.49 Perf Half Y-50.86%
Sales0.00M P/B- EPS next Y75.86% ROA-99.93% Short Interest1.22M Perf YTD-61.13%
Book/sh-0.09 P/C2.36 EPS next 5Y29.64% ROE- 52W High3.02 -77.22% Perf Year-38.02%
Cash/sh0.29 P/FCF- EPS past 3/5Y46.92% 29.27% ROIC-84.53% 52W Low0.61 12.64% Perf 3Y-69.69%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.25% 8.20% Perf 5Y-92.15%
Dividend TTM- EV/Sales- EPS Y/Y TTM57.08% Oper. Margin- ATR (14)0.06 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.52 Sales Y/Y TTM- Profit Margin- RSI (14)44.17 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.69 EPS Q/Q46.01% SMA20-1.56% Beta3.25 Target Price7.00
Payout- Debt/Eq- Sales Q/Q- SMA50-12.47% Rel Volume0.41 Prev Close0.68
Employees9 LT Debt/Eq- EarningsAug 05 BMO SMA200-44.13% Avg Volume818.04K Price0.69
IPOMay 25, 2018 Option/ShortNo / Yes EPS/Sales Surpr.-18.18% - Trades Volume217,136 Change0.58%
Date Action Analyst Rating Change Price Target Change
May-28-21Upgrade Gabelli & Co Sell → Hold
Mar-15-21Upgrade H.C. Wainwright Neutral → Buy $2.50
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Aug-20-25 08:00AM
Aug-05-25 07:00AM
Jul-29-25 08:00AM
Jul-02-25 04:30PM
Jun-30-25 07:00AM
07:00AM Loading…
Jun-25-25 07:00AM
Jun-11-25 07:00AM
May-19-25 07:00AM
May-14-25 03:08AM
02:52AM
May-13-25 07:00AM
May-06-25 07:00AM
Apr-30-25 04:30PM
Apr-29-25 08:00AM
Apr-14-25 08:00AM
02:06AM Loading…
Feb-08-25 02:06AM
12:16AM
Feb-07-25 07:00AM
Jan-31-25 08:00AM
Nov-21-24 08:30AM
Nov-15-24 02:10AM
Nov-14-24 07:00AM
Nov-11-24 08:00AM
Oct-28-24 10:19AM
07:49AM
05:00AM
Oct-25-24 11:03AM
Oct-10-24 08:30AM
Oct-09-24 05:00PM
Sep-24-24 10:33AM
07:00AM Loading…
Sep-10-24 07:00AM
Sep-06-24 04:30PM
Aug-17-24 08:09AM
Aug-14-24 07:00AM
Aug-10-24 08:18AM
Aug-07-24 04:30PM
Aug-06-24 05:30PM
Aug-02-24 08:00AM
Jul-22-24 07:30AM
Jun-21-24 08:00AM
Jun-05-24 08:00AM
May-31-24 08:00AM
May-14-24 08:21AM
May-13-24 10:49PM
11:53AM
07:00AM
May-06-24 08:00AM
Apr-29-24 08:00AM
Apr-02-24 10:22AM
Mar-29-24 12:09AM
Mar-28-24 11:53AM
07:00AM
Mar-21-24 04:30PM
Mar-15-24 08:00AM
Mar-07-24 07:57AM
Mar-06-24 08:00AM
Feb-01-24 03:03PM
Jan-30-24 07:00AM
Dec-04-23 08:00AM
Nov-15-23 12:22PM
12:08AM
Nov-14-23 07:00AM
Nov-07-23 08:30AM
Oct-24-23 08:00AM
Oct-12-23 09:15AM
Aug-11-23 10:10PM
07:00AM
Aug-04-23 05:00PM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-12-23 06:23PM
May-12-23 07:00AM
May-10-23 09:16AM
Apr-20-23 05:00PM
Apr-13-23 12:00PM
Mar-18-23 02:06AM
Mar-16-23 09:16PM
07:00AM
Mar-09-23 05:00PM
Jan-11-23 06:00PM
Dec-15-22 08:00AM
Nov-10-22 07:00AM
Nov-03-22 08:00AM
Oct-20-22 07:30AM
Oct-17-22 05:19PM
Sep-19-22 07:30AM
Sep-07-22 09:15AM
Sep-01-22 04:15PM
Aug-17-22 09:45AM
Aug-16-22 09:00PM
Aug-12-22 07:00AM
Jul-11-22 02:31PM
07:30AM
Jul-06-22 04:30PM
Jun-14-22 05:00PM
May-13-22 07:00AM
May-11-22 08:00AM
Apr-25-22 05:06PM
Mar-28-22 10:19AM
07:00AM
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dunne Michael W.DirectorAug 08 '25Buy0.7215,00010,854235,001Aug 12 07:00 AM